<DOC>
	<DOCNO>NCT02824510</DOCNO>
	<brief_summary>The objective study : 1 ) evaluate effect moderate exercise SG evolution without insulin dose modification patient T1D continuous subcutaneous insulin infusion ( CSII ) multiple daily injection ( MDI ) therapy , compare difference 2 group ; 2 ) evaluate impact insulin dose modification ( bolus , basal , reduction increase , base SG evolution profile obtain first exercise ) and/or moderate exercise T1D child CSII MDI regimen , compare difference 2 group .</brief_summary>
	<brief_title>Evaluation Glycemic Changes During Exercise Children With Type 1 Diabetes</brief_title>
	<detailed_description>Intervention procedure : ) The patient first assign standardize moderate-to-vigorous exercise SG determination ; b ) similar exercise repeat preemptive adaptation insulin dose ( tailored SG evolution first exercise ) determination potential influence SG evolution . Intervention Plan : - At first visit ( day [ &gt; 18h ] exercise ) : set Continuous Glucose Monitoring System - At second visit : moderate-to-vigorous exercise treadmill . - At third visit ( 2 day exercise ) : removal CGMS - At fourth visit ( day [ &gt; 18h ] fifth visit ) : set Continuous Glucose Monitoring System - At fifth visit : moderate exercise treadmill , insulin dose modification ( basal rate , bolus , reduction , increase ) - At sixth visit ( 2 day exercise ) : removal CGMS - Total number visit : 6 - The exercise perform 1 2 hour breakfast lunch ; second exercise perform ≥2 week first exercise . Controls : - Moderate exercise without modification insulin dose MDI patient ( comparison CSII patient ) . MDI patient match CSII patient accord gender , age , BMI ( ±0.5 z-score ) HbA1C level ( ±1 % ) exclude bias patient allocation . - Moderate exercise without modification insulin dose first visit ( comparison modification insulin dose ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosis T1D ( accord ISPAD 2011 guideline ) T1D outside partial remission phase ( define accord IDAA1C definition [ Diabetes Care 2007 ] , equal A1C ( % ) + [ 4 x insulin dose ( unit per kilogram per 24 h ) ] least &gt; 2 year T1D diagnosis ( define first day insulin therapy ) Nontype 1 diabetes Severe neonatal asphyxia ( define Apgar score 3 less 5 min ) , child bear small gestational age , chronic systemic disease , active malignancy , hypothyroidism , hypopituitarism , developmental delay , bladder dysfunction , obesity , carnitine deficiency , βoxidation defect , cardiac malformation , dysrhythmia Intake drug interfere insulin sensitivity ( e.g . corticosteroid , GH ) . HbA1C &gt; 9.5 % time enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>